Instrument Inactif

Communiqués Abpro Corporation Nasdaq

Actions

15/01	Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference	AQ
06/01	Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	AQ
15/12	Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers	AQ
09/12	Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives	AQ
04/11	Abpro and Celltrion to Present Preclinical Data for CT-P72/ABP-102 at SITC 2025, Highlighting a Next-Generation HER2×CD3 T-Cell Engager	AQ
03/11	Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025	GL
27/04/25	Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager	GL
27/04/25	Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager	AQ
25/03/25	Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025	GL
10/03/25	Abpro Statement on the Departure of Former CEO Ian Chan	GL
12/12/24	Abpro Holdings Celebrates Closing of Business Combination with Nasdaq Bell Ringing	GL